{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:23:12Z","timestamp":1780057392782,"version":"3.54.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019256","name":"NIHR Great Ormond Street Hospital Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.hoc.2022.03.010","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T07:29:12Z","timestamp":1656314952000},"page":"813-827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Gene Therapy for Inborn Errors of Immunity"],"prefix":"10.1016","volume":"36","author":[{"given":"Kritika","family":"Chetty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben C.","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.hoc.2022.03.010_bib1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s10875-014-0102-8","article-title":"Prevalence and morbidity of primary immunodeficiency diseases, United States 2001-2007","volume":"34","author":"Kobrynski","year":"2014","journal-title":"J\u00a0Clin Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.010_bib2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s10875-020-00758-x","article-title":"Human Inborn Errors of Immunity: 2019\u00a0Update of the IUIS Phenotypical Classification","volume":"40","author":"Bousfiha","year":"2020","journal-title":"J\u00a0Clin Immunol"},{"issue":"23","key":"10.1016\/j.hoc.2022.03.010_bib3","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2013-02-380105","article-title":"How i treat severe combined immunodeficiency","volume":"122","author":"Gaspar","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.010_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/1744666X.2018.1424627","article-title":"Hematopoietic cell transplantation in primary immunodeficiency \u2013 conventional and emerging indications","volume":"14","author":"Slatter","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.010_bib5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1401177","article-title":"Transplantation Outcomes for Severe Combined Immunodeficiency, 2000\u20132009","volume":"371","author":"Pai","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.hoc.2022.03.010_bib6","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/blood-2017-05-781849","article-title":"Immune reconstitution and survival of 100 SCID patients post\u2013hematopoietic cell transplant: a PIDTC natural history study","volume":"130","author":"Heimall","year":"2017","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.hoc.2022.03.010_bib7","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/blood-2018-03-840702","article-title":"SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery","volume":"132","author":"Haddad","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2022.03.010_bib8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/sj.bmt.1702831","article-title":"Bone marrow transplantation for T-B- severe combined immunodeficiency disease in Athabascan-speaking native Americans","volume":"27","author":"O\u2019Marcaigh","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"5235","key":"10.1016\/j.hoc.2022.03.010_bib9","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1126\/science.270.5235.470","article-title":"Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients","volume":"270","author":"Bordignon","year":"1995","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.010_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0092-8674(93)90167-O","article-title":"Interleukin-2 receptor \u03b3 chain mutation results in X-linked severe combined immunodeficiency in humans","volume":"73","author":"Noguchi","year":"1993","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.010_bib11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2018.08.027","article-title":"The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018)","volume":"143","author":"Dvorak","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5466","key":"10.1016\/j.hoc.2022.03.010_bib12","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease","volume":"288","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.hoc.2022.03.010_bib13","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa012616","article-title":"Sustained correction of X-linked severe combined immunodeficiency by ex\u00a0vivo gene therapy","volume":"346","author":"Hacein-Bey-Abina","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.010_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa1000164","article-title":"Efficacy of Gene Therapy for X-Linked Severe Combined Immunodeficiency","volume":"363","author":"Hacein-Bey-Abina","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9452","key":"10.1016\/j.hoc.2022.03.010_bib15","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(04)17590-9","article-title":"Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector","volume":"364","author":"Gaspar","year":"2004","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.hoc.2022.03.010_bib16","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.hoc.2022.03.010_bib17","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.010_bib18","doi-asserted-by":"crossref","first-page":"e20190607","DOI":"10.1084\/jem.20190607","article-title":"Gene therapy for severe combined immunodeficiencies and beyond","volume":"217","author":"Fischer","year":"2020","journal-title":"J\u00a0Exp Med"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.010_bib19","first-page":"347","article-title":"LMO2 associated clonal T\u00a0cell proliferation 15 years after gamma-retrovirus mediated gene therapy for SCIDX1","volume":"25","author":"Six","year":"2017","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.010_bib20","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat Med"},{"issue":"227","key":"10.1016\/j.hoc.2022.03.010_bib21","doi-asserted-by":"crossref","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome-long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci Translational Med"},{"issue":"15","key":"10.1016\/j.hoc.2022.03.010_bib22","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1404588","article-title":"A\u00a0modified \u03b3-retrovirus vector for X-linked severe combined immunodeficiency","volume":"371","author":"Hacein-Bey-Abina","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"335","key":"10.1016\/j.hoc.2022.03.010_bib23","doi-asserted-by":"crossref","first-page":"335ra57","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"de Ravin","year":"2016","journal-title":"Sci Translational Med"},{"issue":"16","key":"10.1016\/j.hoc.2022.03.010_bib24","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.hoc.2022.03.010_bib25","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jama.2014.9132","article-title":"Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United States","volume":"312","author":"Kwan","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.010_bib26","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0022-3476(76)80793-7","article-title":"The chondro-osseous dysplasia of adenosine deaminase deficiency with severe combined immunodeficiency","volume":"89","author":"Cederbaum","year":"1976","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.010_bib27","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jpeds.2003.10.055","article-title":"Bilateral sensorineural deafness in adenosine deaminase-deficient severe combined immunodeficiency","volume":"144","author":"Albuquerque","year":"2004","journal-title":"J\u00a0Pediatr"},{"issue":"21","key":"10.1016\/j.hoc.2022.03.010_bib28","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJM199605233342104","article-title":"Hepatic Dysfunction as a Complication of Adenosine Deaminase Deficiency","volume":"334","author":"Bollinger","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"7940","key":"10.1016\/j.hoc.2022.03.010_bib29","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(75)90238-X","article-title":"Successful fetal transplantation in a child with severe combined immunodeficiency","volume":"306","author":"Keightley","year":"1975","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.010_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1067\/mpd.2001.115023","article-title":"Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency","volume":"139","author":"Rogers","year":"2001","journal-title":"J\u00a0Pediatr"},{"issue":"6","key":"10.1016\/j.hoc.2022.03.010_bib31","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.jaci.2012.02.003","article-title":"Pulmonary alveolar proteinosis in patients with adenosine deaminase deficiency","volume":"129","author":"Grunebaum","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.010_bib32","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jaci.2011.10.028","article-title":"Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase\u2013deficient severe combined immune deficiency","volume":"129","author":"Kesserwan","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.010_bib33","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s10875-020-00777-8","article-title":"Urogenital abnormalities in adenosine deaminase deficiency","volume":"40","author":"Pajno","year":"2020","journal-title":"J\u00a0Clin Immunol"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.010_bib34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clim.2005.07.006","article-title":"Long-term efficacy of enzyme replacement therapy for Adenosine deaminase (ADA)-deficient Severe Combined Immunodeficiency (SCID)","volume":"117","author":"Chan","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.hoc.2022.03.010_bib35","article-title":"Long-Term Immune Recovery After Hematopoietic Stem Cell Transplantation for ADA Deficiency: a Single-Center Experience","author":"Kreins","year":"2021","journal-title":"J\u00a0Clin Immunol"},{"issue":"17","key":"10.1016\/j.hoc.2022.03.010_bib36","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood-2011-12-396879","article-title":"Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency","volume":"120","author":"Hassan","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2022.03.010_bib37","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2002-09-2800","article-title":"Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial","volume":"101","author":"Muul","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.010_bib38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nm0502-423","article-title":"Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement","volume":"8","author":"Aiuti","year":"2002","journal-title":"Nat Med"},{"issue":"5577","key":"10.1016\/j.hoc.2022.03.010_bib39","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.010_bib40","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2022.03.010_bib41","doi-asserted-by":"crossref","first-page":"737","DOI":"10.15252\/emmm.201707573","article-title":"Gene therapy for ADA-SCID, the first marketing approval of an ex\u00a0vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products","volume":"9","author":"Aiuti","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.010_bib42","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ymthe.2006.06.007","article-title":"Successful Reconstitution of Immunity in ADA-SCID by Stem Cell Gene Therapy Following Cessation of PEG-ADA and Use of Mild Preconditioning","volume":"14","author":"Gaspar","year":"2006","journal-title":"Mol Ther"},{"issue":"97","key":"10.1016\/j.hoc.2022.03.010_bib43","doi-asserted-by":"crossref","first-page":"97ra80","DOI":"10.1126\/scitranslmed.3002716","article-title":"Immunodeficiency: Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci Translational Med"},{"issue":"18","key":"10.1016\/j.hoc.2022.03.010_bib44","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2012-02-400937","article-title":"Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans","volume":"120","author":"Candotti","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.010_bib45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2016-01-688226","article-title":"Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"128","author":"Cicalese","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2022.03.010_bib46","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood.2020010260","article-title":"Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency","volume":"138","author":"Reinhardt","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2022.03.010_bib47","unstructured":"Orchard Therapeutics. Press Releases Orchard Statement on Strimvelis\u00ae, a Gammaretroviral Vector-Based Gene Therapy for ADA-SCID.; 2020."},{"issue":"21","key":"10.1016\/j.hoc.2022.03.010_bib48","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","article-title":"Autologous Ex\u00a0Vivo lentiviral gene therapy for adenosine deaminase deficiency","volume":"384","author":"Kohn","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.010_bib49","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jaci.2018.08.024","article-title":"Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency","volume":"143","author":"Kohn","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.010_bib50","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/hmg\/9.4.583","article-title":"A\u00a0new gene involved in DNA double-strand break repair and V(D)J recombination is located on human chromosome 10p","volume":"9","author":"Moshous","year":"2000","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.010_bib51","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0092-8674(01)00309-9","article-title":"Artemis, a novel DNA double-strand break repair\/V(D)J recombination protein, is mutated in human severe combined immune deficiency","volume":"105","author":"Moshous","year":"2001","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.010_bib52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1749-6632.2011.06322.x","article-title":"DNA repair: the link between primary immunodeficiency and cancer","volume":"1246","author":"de Miranda","year":"2011","journal-title":"Ann N Y Acad Sci"},{"issue":"17","key":"10.1016\/j.hoc.2022.03.010_bib53","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1182\/blood-2008-09-177923","article-title":"Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency","volume":"113","author":"Neven","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.010_bib54","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1182\/blood-2013-01-476432","article-title":"SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID","volume":"123","author":"Schuetz","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.010_bib55","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.bbmt.2019.12.589","article-title":"Early Outcome of a Phase I\/II Clinical Trial (NCT03538899) of Gene-Corrected Autologous CD34+ Hematopoietic Cells and Low-Exposure Busulfan in Newly Diagnosed Patients with Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID)","volume":"26","author":"Cowan","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.010_bib56","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1089\/hum.2016.064","article-title":"Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency","volume":"28","author":"Punwani","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"8","key":"10.1016\/j.hoc.2022.03.010_bib57","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/mt.2008.118","article-title":"Stable and functional lymphoid reconstitution in artemis-deficient mice following lentiviral artemis gene transfer into hematopoietic stem cells","volume":"16","author":"Benjelloun","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.hoc.2022.03.010_bib58","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.omtm.2019.08.014","article-title":"Biosafety Studies of a Clinically Applicable Lentiviral Vector for the Gene Therapy of Artemis-SCID","volume":"15","author":"Charrier","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.010_bib59","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1749-6632.1992.tb24626.x","article-title":"Function and Control of Recombination-Activating Gene Activity","volume":"651","author":"Alt","year":"1992","journal-title":"Ann New York Acad Sci"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.010_bib60","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2005-05-2032","article-title":"Long-term immune reconstitution in RAG-1-deficient mice treated by retroviral gene therapy: a balance between efficiency and toxicity","volume":"107","author":"Lagresle-Peyrou","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2022.03.010_bib61","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/leu.2011.106","article-title":"Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer","volume":"25","author":"Pike-Overzet","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.010_bib62","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jaci.2013.10.009","article-title":"Recombination-activating gene 1 (Rag1)\u2013deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome","volume":"133","author":"van Til","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.hoc.2022.03.010_bib63","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.omtm.2020.03.016","article-title":"Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID","volume":"17","author":"Garcia-Perez","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.010_bib64","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jaci.2017.11.015","article-title":"Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation","volume":"142","author":"Capo","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.hoc.2022.03.010_bib65","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1182\/blood-2002-03-0782","article-title":"Gene therapy of RAG-2\u2212\/\u2212 mice: sustained correction of the immunodeficiency","volume":"100","author":"Yates","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2022.03.010_bib66","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1038\/mt.2012.110","article-title":"Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene","volume":"20","author":"van Til","year":"2012","journal-title":"Mol Ther"},{"issue":"24","key":"10.1016\/j.hoc.2022.03.010_bib67","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/sj.gt.3302558","article-title":"Retroviral transduction of IL-7R\u03b1 into IL-7R\u03b1\u2212\/\u2212 bone marrow progenitors: correction of lymphoid deficiency and induction of neutrophilia","volume":"12","author":"Jiang","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.hoc.2022.03.010_bib68","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood-2021-151040","article-title":"Rescue of Murine IL-7 receptor deficiency with human IL-7 receptor gene therapy","volume":"138","author":"Triebwasser","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2022.03.010_bib69","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1084\/jem.183.6.2687","article-title":"In\u00a0vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction","volume":"183","author":"Candotti","year":"1996","journal-title":"J\u00a0Exp Med"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.010_bib70","doi-asserted-by":"crossref","first-page":"S449","DOI":"10.1016\/S1525-0016(16)41606-0","article-title":"1164. A clinical attempt to treat JAK3-deficient SCID using retroviral-mediated gene transfer to bone marrow CD34+ Cells","volume":"7","author":"Sorrentino","year":"2003","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.010_bib71","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1006\/mthe.2000.0116","article-title":"VSV-G Pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum","volume":"2","author":"DePolo","year":"2000","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.010_bib72","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3390\/v12030332","article-title":"FV vectors as alternative gene vehicles for gene transfer in HSCs","volume":"12","author":"Simantirakis","year":"2020","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.hoc.2022.03.010_bib73","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1182\/bloodadvances.2018016451","article-title":"Rapid immune reconstitution of SCID-X1 canines after G-CSF\/AMD3100 mobilization and in\u00a0vivo gene therapy","volume":"2","author":"Humbert","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.010_bib74","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/mt.2009.282","article-title":"Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells","volume":"18","author":"Trobridge","year":"2010","journal-title":"Mol Ther"},{"issue":"1\u20132","key":"10.1016\/j.hoc.2022.03.010_bib75","first-page":"113","article-title":"In\u00a0Vivo Gene Therapy for Canine SCID-X1\u00a0Using Cocal-Pseudotyped Lentiviral Vector","volume":"32","author":"Rajawat","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"10","key":"10.1016\/j.hoc.2022.03.010_bib76","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/sj.cgt.7700232","article-title":"Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need for tight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome","volume":"7","author":"Sacco","year":"2000","journal-title":"Cancer Gene Ther"},{"issue":"7504","key":"10.1016\/j.hoc.2022.03.010_bib77","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature13420","article-title":"Targeted genome editing in human repopulating haematopoietic stem cells","volume":"510","author":"Genovese","year":"2014","journal-title":"Nature"},{"issue":"411","key":"10.1016\/j.hoc.2022.03.010_bib78","doi-asserted-by":"crossref","first-page":"eaan0820","DOI":"10.1126\/scitranslmed.aan0820","article-title":"Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1","volume":"9","author":"Schiroli","year":"2017","journal-title":"Sci Translational Med"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.010_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13620-5","article-title":"Gene correction for SCID-X1 in long-term hematopoietic stem cells","volume":"10","author":"Pavel-Dinu","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.010_bib80","first-page":"1","article-title":"Newborn Screening for Severe Combined Immunodeficiency in the United States: Lessons Learned","volume":"39","author":"Dorsey","year":"2019","journal-title":"Immunol Allergy Clin"},{"issue":"19","key":"10.1016\/j.hoc.2022.03.010_bib81","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/blood-2018-06-853879","article-title":"Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice","volume":"133","author":"Kwon","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2022.03.010_bib82","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat Biotechnol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858822000314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858822000314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:16:59Z","timestamp":1760185019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858822000314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0889858822000314"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2022.03.010","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene Therapy for Inborn Errors of Immunity","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2022.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}